By Sabela Ojea
Eyenovia said it hired Chardan as its financial adviser as it goes through a business review that includes a potential sale of the company.
The New York-based ophthalmic technology company on Monday said it will use Chardan to continue to asses strategic alternatives such as a business combination, a reverse merger, an asset sale, or a combination of alternatives, while also carefully managing its expenses.
Eyenovia hasn't yet made any final decisions or set a deadline to conclude its review.
Eyenovia ended the Sept. 30 quarter with an unrestricted cash and cash equivalents position of around $7.2 million, down from $14.8 million as of Dec. 31, 2023. "Eyenovia continues to evaluate a range of options to secure long-term financing," the company said in November.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 06, 2025 07:39 ET (12:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.